![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1664188
¼¼°èÀÇ TROP2 Ç×ü ½ÃÀå : ±âȸ ¹× ÀÓ»ó½ÃÇè µ¿Çâ(2030³â)Global TROP2 Antibody Market Opportunity & Clinical Trials Insight 2030 |
TROP2(À¶¸ð¼¼Æ÷ Ç¥¸é Ç׿ø 2)´Â ´Ù¾çÇÑ ¾Ï°úÀÇ ½Î¿ò¿¡¼ Áß¿äÇÑ Ä¡·á Ç¥ÀûÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. ÀÌ IÇü ¸· °üÅë ´ç´Ü¹éÁúÀº TACSTD2 À¯ÀüÀÚ¿¡ ÀÇÇØ ¾ÏȣȵǾî ÀÖÀ¸¸ç, ƯÈ÷ EpCAM À¯µµ ½ÅÈ£Àü´ÞÀ» Á¶ÀýÇÔÀ¸·Î½á ¼¼Æ÷ ½ÅÈ£Àü´Þ °æ·ÎÀÇ Á¶Àý¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. TROP2´Â ¸¹Àº »óÇǼº ¾Ï¿¡¼ °ú¹ßÇöµÇ¾î Á¾¾ç Áõ½Ä·ü°ú ÀüÀ̸¦ À¯¹ßÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ¶ÇÇÑ, TROP2ÀÇ °ú¹ßÇöÀº ƯÈ÷ °íÇü¾Ï¿¡¼ ºÒ·®ÇÑ ¿¹ÈÄ¿Í °ü·ÃÀÌ ÀÖ¾î ¾Ï Ç¥Àû Ä¡·áÀÇ ÀÌ»óÀûÀΠǥÀûÀÌ µÇ°í ÀÖ½À´Ï´Ù.
±âÁ¸ÀÇ ¾Ï Ä¡·á´Â ½É°¢ÇÑ ºÎÀÛ¿ë°ú ƯÁ¤ ȯÀÚ±º¿¡¼ÀÇ ºñÈ¿´É µî ÇѰ谡 ÀÖ¾î »õ·Î¿î Á¢±Ù¹ýÀÇ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. Ç¥ÀûÄ¡·á ºÐ¾ß´Â »õ·Î¿î ¾Ï Ç׿ø, ¼ö¿ëü, ¹ÙÀÌ¿À¸¶Ä¿¿¡ ÃÊÁ¡À» ¸ÂÃá Ç¥ÀûÄ¡·á ºÐ¾ß´Â ÃÖ±Ù °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» °ÅµìÇϰí ÀÖÀ¸¸ç, TROP2 Ç¥Àû Ä¡·áÁ¦´Â ¿©·¯ ÁÖ¿ä ¾ÏÁ¾¿¡¼ ³ôÀº ¾ÈÀü¼º°ú Ä¡·á È¿°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº Á¾¾ç ºÎÀ§¿¡ Á÷Á¢ ¼¼Æ÷µ¶¼º ¾à¹°À» Àü´ÞÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, ±âÁ¸ Ä¡·áÀÇ ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.
2025³â 2¿ù ÇöÀç 3°³ÀÇ TROP2 Ç¥Àû Ä¡·áÁ¦°¡ ÀÓ»ó ½ÂÀÎÀ» ¹Þ¾ÒÀ¸¸ç, ÀÌ´Â ÀÌ Á¢±Ù¹ýÀÇ »ó¿ëÈ¿¡ ÀÖ¾î Áß¿äÇÑ ÀÌÁ¤Ç¥°¡ µÇ°í ÀÖ½À´Ï´Ù. ù ¹øÂ°´Â Æ®·Îµ¨ºñ(¼ººÐ¸í: »ç½ÃÅõÁÖ¸¿ °íºñÅ×Ä)·Î ÀüÀ̼º »ïÁßÀ½¼ºÀ¯¹æ¾Ï(TNBC) Ä¡·áÁ¦·Î 2020³â FDAÀÇ Á¶±â ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌÈÄ Æ®·Îµ¨ºñ´Â 2021³â¿¡ Àüü ½ÂÀÎÀ» ¹Þ¾ÒÀ¸¸ç, 2023³â¿¡´Â HR/HER2 ÀüÀ̼º À¯¹æ¾ÏÀ¸·Î ÀûÀÀÁõÀ» È®´ëÇß½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ½ÂÀÎÀº 2024³â ÇϹݱâ Áß±¹¿¡¼ TNBC ÀûÀÀÁõÀ¸·Î »ç½ÃÅõÁÖ¸¿ Ƽ·ç¸ðÅ×Ä(SKB264)ÀÌ ½ÂÀÎµÈ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ¾Æ½ºÆ®¶óÁ¦³×Ä«¿Í ´ÙÀÌÀÌÂî»êÄì°¡ °³¹ßÇÑ ADCÀÎ ´ÙÆ®·Î¿þÀÌ(dato-dxd)°¡ ¹Ì±¹°ú ÀϺ»¿¡¼ À¯¹æ¾Ï ÀûÀÀÁõÀ¸·Î ½ÂÀεǾú½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÂÀÎÀº ¾Ï ¿µ¿ª¿¡¼ TROP2 Ç¥Àû Ä¡·áÁ¦ÀÇ ¿ªÇÒ Áõ°¡¿Í ½ÃÀå ÀáÀç·Â È®´ë¸¦ °Á¶Çϰí ÀÖ½À´Ï´Ù.
Æ®·Îµ¨ºñÀÇ »ó¾÷Àû ¼º°øÀº TROP2 Ç¥Àû Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁøÁ¦ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¾à¹°ÀÇ ¼º°øÀº TROP2 °æ·Î¿¡ ´ëÇÑ ´õ ¸¹Àº ¿¬±¸¿Í ÅõÀÚ¸¦ Ã˹߽ÃÄ×À¸¸ç, ¿©·¯ Á¦¾à»ç ¹× »ý¸í°øÇÐ ±â¾÷µéÀÌ TROP2 Ç¥Àû¿¡ ´ëÇÑ ÅõÀÚ¸¦ °ÈÇϰí ÀÖÀ¸¸ç, TROP2 ºÐ¾ßÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Gilead, AstraZeneca, Daiichi Sankyo, Klus Pharma, Biothera, Escugen Biotechnology, Shanghai Junshi Biosciences µîÀÌ ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷ Áß »ó´ç¼ö°¡ TROP2¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Ä¡·áÁ¦¸¦ ÀÓ»ó ÆÄÀÌÇÁ¶óÀο¡ Æ÷ÇÔ½Ã۰í ÀÖÀ¸¸ç, ´Ù¼öÀÇ Èĺ¸¹°ÁúÀÌ °³¹ß ÃÊ±â ¹× Á߱⠴ܰ迡 ÀÖ½À´Ï´Ù.
OBI-992, JS108, ESG-401, SHR-A1921 µî ¿©·¯ TROP2 Ç¥Àû Ä¡·áÁ¦°¡ ÀÓ»ó½ÃÇè ÁßÀÔ´Ï´Ù. ´ÜŬ·ÐÇ×ü, Ç×ü¾à¹°Á¢ÇÕü(ADC), ¸é¿ªÄ¡·áÁ¦, ¼¼Æ÷ Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ À̵é Èĺ¸¹°ÁúÀº Ä¡·á°¡ ¾î·Á¿î ¾ÏȯÀÚÀÇ Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖÀ¸¸ç, TROP2 Ç¥Àû Ä¡·áÁ¦ ½ÃÀåÀº ´õ ¸¹Àº Ä¡·áÁ¦°¡ ÆÄÀÌÇÁ¶óÀÎÀ» Åë°úÇÔ¿¡ µû¶ó »ó´çÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
½ÃÀå ¿ªÇÐ Ãø¸é¿¡¼ º¼ ¶§, ÀÌ ºÎ¹®Àº Áö¼ÓÀûÀ¸·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, TrodelvyÀÇ ÀÓ»óÀû ¼º°ø, ÅõÀÚ Áõ°¡, TROP2 Ç¥Àû Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀÇ Áõ°¡¿¡ ÈûÀÔ¾î ÀÌ ½ÃÀåÀº Å« ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¾çÇÑ ¾ÏÁ¾¿¡ Àû¿ëµÇ´Â TROP2 Ç¥Àû Ä¡·áÀÇ Ä¡·á °¡´É¼ºÀº ¹«±Ã¹«ÁøÇÕ´Ï´Ù. ´õ ¸¹Àº Ä¡·á¹ýÀÌ ½ÂÀÎµÇ°í ½ÃÀå¿¡ ÁøÀÔÇÔ¿¡ µû¶ó TROP2 Ç¥Àû Ä¡·áÀÇ »ó¾÷Àû Ãø¸éÀº Áö¼ÓÀûÀ¸·Î °³Ã´µÇ¾î ȯÀÚ¿Í Á¦¾à»ç ¸ðµÎ¿¡°Ô »õ·Î¿î ±âȸ¸¦ Á¦°øÇÒ °ÍÀÔ´Ï´Ù.
°á·ÐÀûÀ¸·Î, Ä¡·á Ç¥ÀûÀ¸·Î¼ÀÇ TROP2´Â ¾Ï Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿Ã ¼ö ÀÖ´Â Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ¹Ì 3°³ÀÇ ¾à¹°ÀÌ ½ÂÀεǾú°í, ´õ ¸¹Àº ¾à¹°ÀÌ °³¹ß ÁßÀ̱⠶§¹®¿¡ TROP2 Ç¥Àû Ä¡·áÁ¦´Â ¾Ï Ç¥ÀûÄ¡·áÀÇ ÇÙ½ÉÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ´ëÇü Á¦¾à»çµéÀÇ °ü½É Áõ°¡´Â ÀÓ»ó½ÃÇè ¾à¹°ÀÇ Áõ°¡¿Í ÇÔ²² ¾Ï ½ÃÀå¿¡¼ ÀÌ Ä¡·á¹ýÀÇ ¹àÀº ¹Ì·¡¸¦ ¾Ï½ÃÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ TROP2 Ç×ü ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ¾àÁ¦ µ¿Çâ, ÀÓ»ó½ÃÇè µ¿Çâ, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ÀÇ °æÀï »óȲ µî¿¡ ´ëÇØ Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
Global TROP2 Antibody Market Opportunity & Clinical Trials Insight 2030 Report Highlights & Inclusions:
TROP2 (Trophoblast cell surface antigen 2) has emerged as a significant therapeutic target in the fight against various cancers. This Type-I transmembrane glycoprotein is encoded by the TACSTD2 gene and plays a key role in regulating cell signaling pathways, particularly by modulating EpCAM-induced signaling. TROP2 is overexpressed in numerous epithelial cancers, leading to an increased tumor growth rate and metastasis. Moreover, its overexpression is associated with poor prognosis, particularly in solid tumors, making it an ideal target for targeted cancer therapies.
As traditional cancer therapies often come with limitations, such as severe side effects and ineffectiveness in certain patient populations, the need for new approaches is growing. The targeted therapy segment has seen significant growth in recent years, with a focus on novel cancer antigens, receptors, and biomarkers. TROP2-targeted therapies represent one such promising avenue, demonstrating high safety and therapeutic efficacy across several major cancer types. These therapies aim to deliver cytotoxic drugs directly to tumor sites, potentially reducing the adverse effects associated with traditional treatments.
As of February 2025, three TROP2-targeted therapies have been approved for clinical use, marking a major milestone in the commercialization of this approach. The first of these is Trodelvy (sacituzumab govitecan), which received accelerated FDA approval in 2020 for the treatment of metastatic triple-negative breast cancer (TNBC). Trodelvy was later granted full approval in 2021 and expanded its indication in 2023 to include HR+/HER2- metastatic breast cancer. Another significant approval came in late 2024, when Sacituzumab Tirumotecan (SKB264) was granted approval in China for TNBC. Additionally, Datroway (dato-dxd), an ADC developed by AstraZeneca and Daiichi Sankyo, was approved for breast cancer in the US and Japan. These approvals highlight the growing role of TROP2-targeted therapies in oncology and the expanding market potential.
The commercial success of Trodelvy has been a key driver of the TROP2-targeted therapy market. The drug's success has spurred additional research and investment into the TROP2 pathway, with several pharmaceutical companies and biotechnology firms intensifying their focus on this target. Major players in the TROP2 space include Gilead, AstraZeneca, Daiichi Sankyo, Klus Pharma, Biothera, Escugen Biotechnology, and Shanghai Junshi Biosciences. Many of these companies have incorporated TROP2-targeted therapies into their clinical pipelines, with numerous candidates in early and mid-stages of development.
Several TROP2-targeted therapies are currently in clinical trials, with investigational drugs such as OBI-992, JS108, ESG-401 and SHR-A1921 showing promise. These candidates, including monoclonal antibodies, antibody-drug conjugates (ADCs), immunotherapies and cell therapies, aim to expand the therapeutic options available to patients with difficult-to-treat cancers. As more of these therapies move through the pipeline, the TROP2-targeted therapy market is expected to experience substantial growth.
In terms of market dynamics, the segment is expected to continue its expansion. Driven by the clinical success of Trodelvy, increasing investments, and a growing pipeline of TROP2-targeted therapies, this market is poised for significant growth. The therapeutic potential of TROP2-targeted treatments is vast, with applications for various cancer types, including TNBC, urothelial carcinoma, and other solid tumors. As more therapies are approved and enter the market, the commercial side of TROP2-targeted therapies will see continued development, offering new opportunities for both patients and pharmaceutical companies.
In conclusion, TROP2 as a therapeutic target holds considerable promise in revolutionizing cancer treatment. With three drugs already approved and many more in the pipeline, TROP2-targeted therapies are positioned to become a cornerstone of targeted cancer therapies. The growing interest from major pharmaceutical companies, along with the increasing number of investigational drugs, signals a bright future for this therapeutic approach in the oncology market.